KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Accounts Payables: 2018-2025

Historic Accounts Payables for Esperion Therapeutics (ESPR) over the last 8 years, with Sep 2025 value amounting to $77.5 million.

  • Esperion Therapeutics' Accounts Payables rose 122.33% to $77.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.5 million, marking a year-over-year increase of 122.33%. This contributed to the annual value of $51.6 million for FY2024, which is 62.84% up from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' Accounts Payables is $77.5 million, which was up 3.76% from $74.7 million recorded in Q2 2025.
  • Esperion Therapeutics' Accounts Payables' 5-year high stood at $77.5 million during Q3 2025, with a 5-year trough of $12.8 million in Q2 2022.
  • Over the past 3 years, Esperion Therapeutics' median Accounts Payables value was $34.9 million (recorded in 2024), while the average stood at $44.2 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first slumped by 66.22% in 2021, then soared by 153.21% in 2025.
  • Esperion Therapeutics' Accounts Payables (Quarterly) stood at $17.6 million in 2021, then spiked by 31.21% to $23.0 million in 2022, then soared by 37.66% to $31.7 million in 2023, then soared by 62.84% to $51.6 million in 2024, then skyrocketed by 122.33% to $77.5 million in 2025.
  • Its Accounts Payables was $77.5 million in Q3 2025, compared to $74.7 million in Q2 2025 and $72.0 million in Q1 2025.